BEDMINSTER, N.J.--(BUSINESS WIRE)--Matinas BioPharma Holdings, Inc. -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Matinas BioPharma. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

BTIG, LLC is acting as sole book-running manager for the offering.

Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development activities for its product candidates, namely MAT9001, and its lipid nano-crystal  platform delivery technology and for working capital and other general corporate purposes.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its LNC platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.